Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20533908 | 0.70 | MAPT (0.45) | L3MBTL1LMNAGAAMAPTKMT2A | |
| SCHEMBL12888873 | 0.70 | MAPT (0.56) | L3MBTL1LMNAGAAMAPTKMT2A | |
| SCHEMBL20533663 | 0.69 | KMT2A (0.43) | L3MBTL1LMNAGAAMAPTKMT2A | |
| SCHEMBL8823005 | 0.65 | KDM4E (0.49) | L3MBTL1MAPTKMT2ANPC1RAB9A | |
| SCHEMBL20528857 | 0.64 | HAVCR2 (0.43) | L3MBTL1LMNAGAASMN1; SMN2 | |
| SCHEMBL23460193 | 0.63 | L3MBTL1 (0.45) | L3MBTL1LMNAGAAMAPTKMT2A | |
| SCHEMBL30992542 | 0.62 | L3MBTL1 (0.41) | L3MBTL1LMNAGAASMN1; SMN2TDP1 | |
| SCHEMBL7381863 | 0.61 | L3MBTL1 (0.37) | L3MBTL1 | |
| SCHEMBL1358101 | 0.61 | — | — | |
| SCHEMBL31167556 | 0.60 | PDE10A (0.57) | LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110520424-B | Heteroaromatic compounds for therapy | 库洛维公司 | 2022-06-21 | — | — | CN | disclosed |
| EP-3606926-B1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2021-05-26 | — | — | EP | disclosed |
| US-11001587-B2 | Substituted indazoles as phosphatidylinositol kinase inhibitors | CUROVIR AB (SE) | 2021-05-11 | — | — | US | disclosed |
| EP-3606926-A1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2020-02-12 | — | — | EP | disclosed |
| US-20200031833-A1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2020-01-30 | — | — | US | disclosed |
| WO-2018185120-A1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2018-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11001587-B2 | Substituted indazoles as phosphatidylinositol kinase inhibitors | PIKFYVE, PI4KA, PIP4K2B | L3MBTL1 1897/4885LMNA 3375/4885GAA 488/4885 |
| US-20200031833-A1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | BECN1, SQSTM1, TFEB | L3MBTL1 1550/4885LMNA 2619/4885GAA 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.